Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
IMMUNIC, INC. director Daniel Vitt received a grant of stock options covering 445,000 shares of common stock as equity compensation. The options have an exercise price of $11.60 per share and expire on April 2, 2036, with all 445,000 options shown as held directly after the grant.
The grant was conditionally approved by the Board of Directors and became effective only after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following thirty-six months, tying director compensation to longer-term company performance.
IMMUNIC, INC. director Michael W. Bonney received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $12.0800 per share and expire on May 15, 2036. They vest in thirty-six equal monthly installments starting on May 15, 2026, providing gradual future ownership potential if exercised. Following this grant, the filing shows Bonney holding options for 100,000 underlying shares.
Immunic, Inc. reported results from its annual stockholder meeting. Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing shares authorized for issuance under the plan by 6,000,000 to a total of 8,644,887 common shares. This expands the pool available for employee and director equity awards.
Three Class III directors – Michael Bonney, Thorvald Nagel and Richard Rudick – were elected to serve until the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
IMMUNIC, INC. granted its Chief Executive Officer, Erik Lundgren, stock options covering 1,000,000 shares of common stock. The options have an exercise price of $13.05 per share and expire on May 22, 2036. They are time-vested: 25% vest on May 22, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on his continued employment.
IMMUNIC, INC. filed an initial Form 3 ownership report for Chief Executive Officer Erik Lundgren. The filing lists him as an officer of the company but does not report any specific share or option holdings and shows no purchases, sales, or other insider transactions. This is a baseline disclosure establishing his status as a reporting person for future ownership and trading reports.
Immunic, Inc. is asking stockholders to approve an amendment to its 2019 Omnibus Equity Incentive Plan to increase the shares authorized for issuance by 6,000,000 shares, bringing the total plan reserve to 8,644,887 shares. This is part of a broader effort to offset dilution from prior financings and maintain competitive equity incentives.
The company will hold a completely virtual annual meeting on June 29, 2026, with holders of 13,621,483 shares of common stock outstanding as of May 26, 2026 eligible to vote. Proposals include electing three Class III directors, approving the equity plan amendment, and ratifying Baker Tilly US, LLP as auditor for 2026.
Immunic discloses that, assuming approval of the plan amendment and exercise of all pre-funded warrants, total potential dilution from equity awards and pre-funded warrants would be approximately 22.2%. The compensation committee has already approved 1,950,819 contingent stock option grants at an exercise price of $11.60 per share, which will only become effective if stockholders approve the plan amendment.
Immunic, Inc. filed a current report describing new clinical data it is presenting from the phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis at the 2026 CMSC meeting. The company issued a press release and posted three posters covering efficacy methodology, patient-reported outcomes and safety.
A late-breaking poster introduces a unified Confirmed Disability Change endpoint that combines confirmed disability worsening and improvement; across three statistical models, results favored vidofludimus calcium over placebo. Another poster shows similar changes in depressive-symptom scores between groups through 120 weeks, with numerically higher patient-reported treatment effectiveness for vidofludimus calcium.
Safety data from 467 patients treated up to 120 weeks show comparable overall adverse event, discontinuation and serious adverse event rates between vidofludimus calcium and placebo, supporting a favorable tolerability profile. Vidofludimus calcium remains an investigational oral therapy in late-stage trials for multiple sclerosis.
Immunic, Inc. has appointed biopharmaceutical executive Erik Lundgren as Chief Executive Officer effective May 22, 2026, with employment beginning June 1, 2026, succeeding Daniel Vitt, Ph.D., who remains on the Board and continues to lead scientific strategy and portfolio advancement.
Lundgren’s employment agreement provides a yearly base salary of $685,000, eligibility for a yearly bonus of at least 60% of base salary, and a guaranteed full-year 2026 bonus at not less than that level, paid in six monthly installments of $68,500 each. He may receive an additional $200,000 cash bonus if the pending phase 3 trial for relapsing multiple sclerosis supports a New Drug Application and he remains employed through March 31, 2027, plus a separate $250,000 cash bonus within one month of the effective date.
Severance protections include lump-sum payments and equity vesting enhancements if he is terminated without cause, resigns for Good Reason, or is not renewed, with richer benefits during a Change of Control Period. The Compensation Committee also granted Lundgren an option to purchase 1,000,000 shares of common stock under the 2026 Inducement Equity Compensation Plan, with 25% vesting on the one-year anniversary of May 22, 2026 and the remainder vesting monthly over 36 months at an exercise price equal to the closing stock price on the approval date.
IMMUNIC, INC. filed an initial insider ownership report for director Michael W. Bonney on Form 3. This filing identifies him as a director of the company but does not list any stock or option transactions, and shows no reported holdings or derivative positions at this time.
Immunic, Inc. appointed Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026. Bonney brings more than three decades of biopharmaceutical leadership, including CEO experience at Cubist Pharmaceuticals and senior commercial roles involved in launching Avonex for multiple sclerosis.
In connection with his appointment, he received options to purchase up to 100,000 shares of Immunic common stock, vesting monthly over three years at an exercise price equal to the May 15, 2026 Nasdaq closing price, subject to shareholder approval of an increase in the 2019 Omnibus Equity Incentive Plan share reserve. Simona Skerjanec will transition from Interim Chairperson to continue as a director, and the Board size increases from nine to ten members. Immunic highlights its late-stage program vidofludimus calcium, currently in phase 3 trials in relapsing multiple sclerosis, with top-line data expected by the end of 2026.